Macronutrients
发表于 2025-3-28 16:52:09
http://reply.papertrans.cn/23/2218/221728/221728_41.png
虚弱
发表于 2025-3-28 19:09:05
http://reply.papertrans.cn/23/2218/221728/221728_42.png
obsession
发表于 2025-3-29 02:06:15
http://reply.papertrans.cn/23/2218/221728/221728_43.png
无聊点好
发表于 2025-3-29 03:39:01
Implantable and Wearable Defibrillator Therapy, the wearable cardiac defibrillator in prevention of sudden cardiac death in high-risk populations remains less clearly defined due to the absence of appropriate designed prospective randomized trials.
BRAWL
发表于 2025-3-29 07:25:30
Clinical Management of Atrial Fibrillation, novel oral anticoagulants and mechanical closure of the left atrial appendage now offer alternative approaches. A thorough understanding of the risks and benefits of all of these treatment approaches, as well as of the clinical status and preferences of each patient, is necessary to provide optimal individualized care to patients with AF.
caldron
发表于 2025-3-29 12:30:58
http://reply.papertrans.cn/23/2218/221728/221728_46.png
GUMP
发表于 2025-3-29 17:26:07
Pathophysiology of Atrial Fibrillation,ed to be due largely to a reentrant mechanism(s), but direct evidence is often lacking and the controversy continues. The development and maintenance of AF are multifactorial and involve dynamic pathophysiologic processes which are in many cases not well defined or understood. This chapter reviews o
bromide
发表于 2025-3-29 22:48:27
Channelopathies: Clinical Presentation and Genetics,discussed in this chapter. As will be outlined, not only can genetics help (or complicate) diagnosis of these channelopathies, important genotype-phenotype correlations have emerged that might aid in risk stratification for these conditions, and genotype specific therapies are available in certain s
完成
发表于 2025-3-30 03:55:44
http://reply.papertrans.cn/23/2218/221728/221728_49.png
Cpap155
发表于 2025-3-30 07:58:18
Antiarrhythmic Drug Management of Atrial Fibrillation,tiarrhythmic is usually made on the basis of the underlying cardiovascular status. In patients with heart failure only dofetilide and amiodarone are considered, and in patients with coronary artery disease disopyramide, flecainide and propafenone are avoided. Dronedarone must be avoided if there is